Arena Pharmaceuticals, Inc. (ARNA) stock has gained 1.67% over the past week and gets a Neutral rating from InvestorsObserver Sentiment Indicator.
Arena Pharmaceuticals, Inc. has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on ARNA!
What is Stock Sentiment?
When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With ARNA Stock Today?
Arena Pharmaceuticals, Inc. (ARNA) stock is down -2.35% while the S&P 500 has risen 0.19% as of 2:29 PM on Monday, Oct 18. ARNA is lower by -$1.48 from the previous closing price of $62.89 on volume of 226,064 shares. Over the past year the S&P 500 has gained 30.72% while ARNA is lower by -20.80%. ARNA lost -$8.17 per share in the over the last 12 months.
To screen for more stocks like Arena Pharmaceuticals, Inc. click here.
More About Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.
Click Here to get the full Stock Report for Arena Pharmaceuticals, Inc. stock.